MetaCap

Dermata Therapeutics (DRMA) vs Ernexa Therapeutics (ERNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dermata Therapeutics is the larger company by market cap ($2.5 million vs $2.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DRMA-54.51%ERNA-43.10%
+7%-25%-57%
Oct 7, 20261 yearNov 20, 2026
DRMA-50.05%ERNA-43.33%
+3%-25%-53%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DRMA versus ERNA key metrics
MetricDRMAERNA
Share price$0.5095$1.36
Market cap$2.51M$2.30M
1-day change-4.23%-16.56%
EPS (TTM)$-3.28$-11.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.56M$-14.08M
52-week high$4.66$37.50
52-week low$0.50$1.35
Distance from 52-week high-89.07%-96.37%
Analyst consensusnonenone
Avg. price target upside+685.08%+2105.88%
Average volume2.78M43.90K
Shares outstanding4.93M1.69M
Employees95
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Dermata Therapeutics

DRMA stock →

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Ernexa Therapeutics

ERNA stock →

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

DRMA vs ERNA FAQ

Which is bigger, Dermata Therapeutics or Ernexa Therapeutics?

Dermata Therapeutics (DRMA) is larger, with a market capitalization of $2.51M compared with $2.30M for Ernexa Therapeutics (ERNA).

Are Dermata Therapeutics and Ernexa Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons